Outcomes of initial hemodialysis access surgery in an Asian population

• Published in: The journal of vascular access Vol. 13; no. 4; p. 409
• Main Authors: Thwaites, Stephen E, Robless, Peter A
• Format: Journal Article
• Language: English
• Published: United States 01.10.2012
• Subjects: Aged; Arteriovenous Shunt, Surgical - adverse effects; Asian Continental Ancestry Group; Catheterization, Central Venous; Female; Humans; Kaplan-Meier Estimate; Kidney Failure, Chronic - ethnology; Kidney Failure, Chronic - mortality; Kidney Failure, Chronic - surgery; Male; Middle Aged; Renal Dialysis; Retrospective Studies; Risk Factors; Sex Factors; Singapore; Time Factors; Treatment Outcome; Upper Extremity - blood supply; Vascular Patency; Singapore
• ISSN: 1724-6032
• DOI: 10.5301/jva.5000064

Access-related morbidity contributes substantially to the costs of hemodialysis. The aim of this study was to examine the outcomes of initial hemodialysis access surgery at a single center in Singapore and to analyze factors which might influence survival of the surgically-created access. Patients undergoing their first hemodialysis access operations between January 2003 and December 2007 were retrospectively identified. Primary and assisted primary patency rates were determined by the Kaplan-Meier method. Data on age, sex, diabetic status, and prior tunneled central venous catheter (CVC) use were analyzed against the outcome of arteriovenous fistulas (AVF). During the study period, 410 primary upper limb access operations were performed: 297 forearm AVF (72.4%), 91 upper arm AVF (22.2%), and 22 arteriovenous grafts (AVG; 5.4%). Men comprised 55.4%, 271 (66.1%) had diabetes, and 316 patients (77.1%) came to surgery with pre-existing CVC. Sixty-two percent of forearm AVF and 67% of arm AVF were used successfully. Age, sex, diabetes, and prior use of a CVC did not significantly affect the ability to use an AVF. Only in the female diabetic subgroup was an earlier loss of primary assisted patency of AVF recorded. In our Asian population, we have demonstrated AVF patency rates equivalent to those of international centers. We now face the challenge of achieving a higher rate of pre-emptive AVF placement with a subsequent reduction in CVC use.